ROCHE'S STRONG 1st QTR GOOD FOR 1992
Group sales at the Swiss pharmaceutical company, Roche Holdings, increased 26% to 3.3 billion Swiss francs ($2.2 billion) in the first quarter of 1991. In local currencies sales growth was 17%. Pharmaceutical sales were said to have increased 32% in the quarter. Full-year results are expected to be good, the company forecast.
In 1991, Roche made pretax profits of just over 2 billion francs, up 40%. Chairman, Fritz Gerber said that growth in operating profits was so strong that it was decided to spend heavily on premarketing of new drugs. Sales for the year were up 18% to 1.5 billion francs. 7% of the increase was attributed to acquisitions, including that of the US biotechnology concern, Genentech. R&D costs for the year were reported to be up 20% to 1.7 billion francs.
Sales were led by Rocephin (ceftriaxone), the third generation cephalosporin used to treat nosocomial infections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze